APA-Zitierstil (7. Ausg.)

Schönfeld, L., Rinke, J., Hinze, A., Nagel, S. N., Schäfer, V., Schenk, T., . . . Ernst, T. (2022). ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia. Leukemia, 36(9), . https://doi.org/10.1038/s41375-022-01648-4

Chicago-Zitierstil (17. Ausg.)

Schönfeld, Lioba, et al. "ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Chronic Myeloid Leukemia." Leukemia 36, no. 9 (2022). https://doi.org/10.1038/s41375-022-01648-4.

MLA-Zitierstil (9. Ausg.)

Schönfeld, Lioba, et al. "ASXL1 Mutations Predict Inferior Molecular Response to Nilotinib Treatment in Chronic Myeloid Leukemia." Leukemia, vol. 36, no. 9, 2022, https://doi.org/10.1038/s41375-022-01648-4.